Email Alert | RSS    帮助

中国防痨杂志 ›› 2015, Vol. 37 ›› Issue (1): 74-79.doi: 10.3969/j.issn.1000-6621.2015.01.014

• 论著 • 上一篇    下一篇

耐多药结核病患者治疗2个月末痰培养情况及影响因素分析

周扬 许卫国 丁晓艳 竺丽梅 虞浩 陈诚 邵燕 陆伟   

  1. 210009 南京,江苏省疾病预防控制中心
  • 收稿日期:2014-11-05 出版日期:2015-01-10 发布日期:2015-02-08
  • 通信作者: 陆伟 E-mail:jsjkmck@163.com

Risk factors associated with sputum culture status after two months’ treatment of multidrug-resistant tuberculosis

ZHOU Yang, XU Wei-guo, DING Xiao-yan, ZHU Li-mei, YU Hao, CHEN Cheng, SHAO Yan, LU Wei   

  1. Department of Chronic Infectious Diseases, Jiangsu Provincial Center for Disease Prevention and Control, Nanjing 210009,China
  • Received:2014-11-05 Online:2015-01-10 Published:2015-02-08
  • Contact: LU Wei E-mail:jsjkmck@163.com

摘要: 目的 了解MDR-TB患者痰菌转阴情况,评价影响痰菌转阴的相关因素。 方法 在徐州市、南通市和镇江市,对痰涂片阳性的肺结核患者的痰液进行培养及结核分枝杆菌菌种鉴定,培养阳性的结核分枝杆菌采用比例法药敏试验判断患者是否耐药。2009年1月1日至2012年6月30日纳入治疗的MDR-TB患者,采用标准化疗方案或个体化化疗方案进行治疗,治疗期间随访监测并实施DOTS 管理。对痰菌检查结果、治疗转归、痰菌转阴影响因素进行分析。完成全疗程的376例MDR-TB患者中男278例,女98例,平均年龄(49.33±15.36)岁。使用SPSS 13.0软件进行单因素χ2检验和多因素logistic回归分析。P<0.05为差异有统计学意义。 结果 治疗2、4、6个月末时,痰培养阴性率分别为58.78%(221/376)、61.97%(233/376)和61.17%(230/376),差异无统计学意义(χ2=0.807,P>0.05)。在治疗2、4、6个月末时,痰培养阴性患者的治疗成功率分别为69.68%(154/221)、71.24%(166/233)和73.48%(169/230),高于培养阳性或未检查的患者(χ2=60.804、82.619、101.047,P值均<0.01)。治疗第2个月末痰培养阳性患者的治疗成功率(31.33%,26/83)也高于治疗第6个月痰培养阳性患者的治疗成功率(16.36%,9/55)(χ2=3.912,P<0.05)。多因素logistic回归分析显示,既往抗结核治疗史(P<0.01,OR=0.205;95%CI:0.070~0.598)、是否对二线药耐药(P<0.05,OR=2.609;95%CI:1.097~6.206)、是否对Km耐药(P<0.05,OR=10.008;95%CI:1.101~90.974)等因素与MDR-TB患者治疗2个月末痰培养转阴呈负相关。 结论 约60%的MDR-TB患者可以在治疗2个月末时痰培养转阴,既往抗结核治疗史、是否对二线药耐药、是否对Km耐药等因素与MDR-TB患者治疗2个月末痰培养转阴有关。

关键词: 结核, 肺/药物疗法, 抗药性, 多种, 细菌, 治疗结果, 回顾性研究

Abstract: Objective To explore the situation of sputum culture conversion, and to evaluate the risk factors of sputum culture conversion for patients with multidrug-resistant TB.  Methods In Xuzhou, Nantong and Zhenjiang, tuberculosis culture and strains identification were carried out on the sputum smear-positive patients, and then drug susceptibility test(DST) was carried out with proportion method. Standardized treatment regimen and individualized regimen were given to MDR-TB patients registered from 1 January 2009 to 30 June 2012. Surveillane and DOTS were implemented to each patient during the treatment. Bacteriologic, treatment outcome and risk factors of sputum culture conversion were evaluated. Three hundred and seventy-six MDR-TB patients had been analyzed, including 278 male, and 98 female. The average age was (49.33±15.36) years old. Data was analyzed using SPSS 13.0, Chi-squared test and logistic regression were used for univariate and multivariate statistics. P value less than 0.05 was considered statistically significant.  Results 58.78% (221/376), 61.97% (233/376) and 61.17% (230/376) patients got culture conversion at 2, 4 and 6 months’ treatment, which had no significant differences between them (χ2=0.807, P>0.05). The treatment success rates of patients got culture conversion at 2, 4 and 6 months were 69.68% (154/221), 71.24% (166/233) and 73.48% (169/230) respectively, which were all higher than patients with culture positive results or without culture results (χ2=60.804,82.619,101.047, P<0.01). The treatment success rate of patients with positive culture at 2 months’ treatment was 31.33% (26/83), and was higher than that at 6 months’ (16.36%, 9/55)(χ2=3.912, P<0.05). In a multivariate analysis, previous TB treatment (P<0.01, OR=0.205; 95%CI: 0.070-0.598), resistance to second line drugs (P<0.05, OR=2.609; 95%CI: 1.097-6.206) and resistance to kanamycin (P<0.05, OR=10.008; 95%CI: 1.101-90.974) had statistically significant negative association with culture conversion at 2 months.  Conclusion About 60% MDR-TB patients get culture conversion at 2 months’ treatment. Previous TB treatment, resistance to second line drugs and resistance to kanamycin are associated with culture conversion at 2 months.

Key words: Tuberculosis, pulmonary/drug therapy, Drug resistance, multiple, bacterial, Treatment outcome, Retrospective study